In mice, the deletion of KRAS has been found to be more lethal than the deletion of NRAS and HRAS; therefore, the use of mutant allele-specific inhibitors in humans was proposed to be a more targeted, viable approach for treating RAS mutant cancers [10,12,13]. This evidence concerns the gene HRAS and cancer.